Bausch + Lomb stock hits 52-week low at $10.46

Bausch + Lomb Corporation (BLCO) shares tumbled to a 52-week low this week, with the stock price touching down at $10.46 USD. According to InvestingPro data, despite maintaining a "GOOD" overall financial health score, the company operates with a significant debt burden. This latest dip underscores a challenging year for the eye health products company, though its revenue grew by approximately 16% in the last twelve months. Analysts remain optimistic, with price targets ranging from $14 to $22. Investors are closely monitoring the company’s performance, as it navigates through market pressures and seeks to regain its footing in a competitive industry. The 52-week low serves as a critical juncture for Bausch + Lomb, as stakeholders consider the company’s strategic moves to bolster its market position and drive future growth. For deeper insights into BLCO’s valuation and growth prospects, including 6 additional ProTips and comprehensive financial analysis, visit InvestingPro.

In other recent news, Bausch + Lomb Corp reported a challenging Q1 2025 with earnings and revenue falling short of analyst expectations. The company posted an earnings per share (EPS) of -$0.07, missing the forecast of $0.02, and reported revenue of $1.14 billion, slightly below the expected $1.15 billion. Despite these setbacks, Bausch + Lomb raised its full-year revenue guidance to $5.0-$5.1 billion, indicating confidence in its future performance. A voluntary recall of Envista lenses impacted revenue by $55 million, posing a risk to short-term financial performance. In terms of analyst coverage, no specific upgrades or downgrades were mentioned, but the company continues to focus on strategic initiatives such as the anticipated approval of the Elios MIGS glaucoma product by year-end. The recall of Envista intraocular lenses was addressed quickly, with the company returning to full production shortly after the issue was identified. Bausch + Lomb’s core business segments, including contact lenses and eye health products, showed growth, with a 5% increase in revenue on a constant currency basis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.